Eriko Takatori
No ORCID on file
· 3 papers in corpus
observational
2026
Objective: Bevacizumab (BEV) and Olaparib (OLA) have demonstrated clinical efficacy as maintenance therapies for first platinum-sensitive recurrent ovarian cancer. However, direct comparisons between these agents independent of homologous …
review
2021
Ovarian cancer has the worst prognosis among gynecological cancers. In particular, clear cell and mucinous carcinomas are less sensitive to chemotherapy. The establishment of new therapies is necessary to improve the treatment outcomes for …
meta-analysis
2016
BACKGROUND: The aims of this report were to describe a case of ovarian adenosquamous carcinoma and to systematically review the pertinent literature. METHODS: We describe a case in which a 57-year-old woman had stage IC ovarian cancer hist…